K34c
Modify Date: 2024-01-13 21:42:37
K34c structure
|
Common Name | K34c | ||
|---|---|---|---|---|
| CAS Number | 939769-93-4 | Molecular Weight | 447.53 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H29N3O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of K34cK34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research[1]. |
| Name | K34c |
|---|
| Description | K34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research[1]. |
|---|---|
| Related Catalog | |
| Target |
α5β1 |
| In Vitro | K34c (20 μM; 24 or 48 h) significantly induces U87MG cells apoptosis in combination with 1 μM Ellipticine (HY-15753)[1]. K34c (20 μM; 48 h) decreases significantly Temozolomide (HY-17364)-induced senescence in cells transfected with control non targeting siRNA without affecting significantly the residual senescence of cells transfected with siRNA specific for p53[1]. K34c (20 μM; 24 h) modulates the p53 pathway. Apoptosis Analysis[1] Cell Line: U87MG cells Concentration: 20 μM Incubation Time: 24 or 48 h Result: Induced apoptosis, led to a significant increase in apoptotic cell death measured by the population of sub-G1 cells in combination with 1 μM Ellipticine (HY-15753). Western Blot Analysis[1] Cell Line: U87MG cells Concentration: 20 μM Incubation Time: 24 h Result: Decreased Ellipticine (HY-15753)- and Temozolomide (HY-17364)-induced activation of p53. |
| References |
| Molecular Formula | C26H29N3O4 |
|---|---|
| Molecular Weight | 447.53 |